Cinryze

(C1 esterase inhibitor)
Cinryze 500 UNT Injection
NO BOXED WARNING

Dosage & administration

For Intravenous Use Only

Routine Prophylaxis Dosing

Adults and adolescents (12 years old and above)

IndicationDoseInfusion rate

Routine prophylaxis against HAE attacks1,000 IU Intravenous every 3 or 4 days *1 mL/min
(10 min)

Children (6 to 11 years old)

IndicationDoseInfusion rate

Routine prophylaxis against HAE attacks500 IU Intravenous every 3 or 4 days *1 mL/min
(5 min)

drug label

Cinryze prescribing information

prior authorization

Cinryze prior authorization resources

Most recent Cinryze prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medicare Prescription Drug Medication Request Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Short Acting Opioid Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Western NY - Specialty Drug Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Feb 27, 2024Arizona - Uniform Prior Authorization Form
Verified: Feb 27, 2024Colorado - Uniform Prior Authorization Form
Verified: Feb 27, 2024Hawaii - Uniform Prior Authorization Form
Verified: Feb 27, 2024Illinois - Uniform Prior Authorization Form
Verified: Feb 27, 2024Indiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Louisiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Michigan - Uniform Prior Authorization Form
Verified: Feb 27, 2024Minnesota - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Mexico - Uniform Prior Authorization Form
Verified: Feb 27, 2024Oregon - Uniform Prior Authorization Form
Verified: Feb 27, 2024Texas - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Learn More

Benefits investigation

One Path Enrollment Form
Learn More

financial assistance

Cinryze financial assistance options

Co-pay savings program

commercial only
One Path Enrollment Form
Enroll in Patient Savings Program
Learn More

PubMed™ | Cinryze

Cinryze PubMed™ News

patient education

Cinryze patient education

Getting started on Cinryze

Instructions For Use: HAE
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

Doctor Discussion Guide
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
HAE Family Tree Worksheet
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
HAE Attack Plan Letter
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Caring for Someone with HAE Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Power of Prevention Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Sign-Up for Information about HAE
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Cinryze
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Effectiveness of Cinryze
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Cinryze
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Cinryze FAQs

1. Is CINRYZE safe to use during pregnancy?There are no specific data available regarding the use of CINRYZE in pregnant women. Animal studies have not been conducted to assess its effects on pregnancy. Whether CINRYZE can cause harm to a developing fetus or affect reproductive capacity in pregnant women is unknown. It should only be administered to a pregnant woman if it is clearly needed.
2. What is the background risk of birth defects and miscarriage in the general U.S. population?In the U.S. general population, the estimated background risk of major birth defects in clinically recognized pregnancies is 2 to 4%, and the risk of miscarriage is estimated to be 15 to 20%.
3. Is there any information on the use of CINRYZE during lactation?There is no available data regarding the presence of CINRYZE in human milk, its effects on breastfed infants, or its impact on milk production. When considering the use of CINRYZE, the benefits of breastfeeding, both for the infant's development and the mother's clinical need, should be weighed against any potential adverse effects on the breastfed child.
4. Has CINRYZE been tested in pediatric patients?Yes, the safety and effectiveness of CINRYZE have been evaluated in pediatric subjects with hereditary angioedema (HAE) aged 7 to 11 years old. Additionally, some subjects under the age of 18 were included in trials, and overall, the safety and tolerability of CINRYZE were found to be similar in pediatric, adolescent, and adult subjects. The pharmacokinetics of CINRYZE were also assessed in pediatric subjects aged 7 to 11 years old.
5. Is CINRYZE suitable for use in geriatric patients?Clinical studies of CINRYZE did not include a sufficient number of subjects aged 65 and over to determine if they respond differently from younger subjects. Reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for an elderly patient should be cautious, typically starting at the lower end of the dosing range, considering the higher likelihood of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.
FAQ Data Source